These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 28558043)

  • 1. Vaccination with a Leishmania infantum HSP70-II null mutant confers long-term protective immunity against Leishmania major infection in two mice models.
    Solana JC; Ramírez L; Corvo L; de Oliveira CI; Barral-Netto M; Requena JM; Iborra S; Soto M
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005644. PubMed ID: 28558043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
    Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
    Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coadministration of the Three Antigenic Leishmania infantum Poly (A) Binding Proteins as a DNA Vaccine Induces Protection against Leishmania major Infection in BALB/c Mice.
    Soto M; Corvo L; Garde E; Ramírez L; Iniesta V; Bonay P; Gómez-Nieto C; González VM; Martín ME; Alonso C; Coelho EA; Barral A; Barral-Netto M; Iborra S
    PLoS Negl Trop Dis; 2015 May; 9(5):e0003751. PubMed ID: 25955652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leishmania major p27 gene knockout as a novel live attenuated vaccine candidate: Protective immunity and efficacy evaluation against cutaneous and visceral leishmaniasis in BALB/c mice.
    Elikaee S; Mohebali M; Rezaei S; Eslami H; Khamesipour A; Keshavarz H; Eshraghian MR
    Vaccine; 2019 May; 37(24):3221-3228. PubMed ID: 31047672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
    Iborra S; Soto M; Carrión J; Alonso C; Requena JM
    Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SIR2-deficient Leishmania infantum induces a defined IFN-gamma/IL-10 pattern that correlates with protection.
    Silvestre R; Cordeiro-Da-Silva A; Santarém N; Vergnes B; Sereno D; Ouaissi A
    J Immunol; 2007 Sep; 179(5):3161-70. PubMed ID: 17709531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intradermal inoculations of low doses of Leishmania major and Leishmania amazonensis metacyclic promastigotes induce different immunoparasitic processes and status of protection in BALB/c mice.
    Courret N; Lang T; Milon G; Antoine JC
    Int J Parasitol; 2003 Oct; 33(12):1373-83. PubMed ID: 14527520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-protective efficacy of Leishmania infantum LiHyD protein against tegumentary leishmaniasis caused by Leishmania major and Leishmania braziliensis species.
    Lage DP; Martins VT; Duarte MC; Costa LE; Tavares GSV; Ramos FF; Chávez-Fumagalli MA; Menezes-Souza D; Roatt BM; Tavares CAP; Coelho EAF
    Acta Trop; 2016 Jun; 158():220-230. PubMed ID: 26976272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inoculation of the
    Soto M; Ramírez L; Solana JC; Cook ECL; Hernández-García E; Requena JM; Iborra S
    Microorganisms; 2021 Feb; 9(2):. PubMed ID: 33673117
    [No Abstract]   [Full Text] [Related]  

  • 10. Distinct immunological states in murine cutaneous leishmaniasis by immunising with different amounts of antigen: the generation of beneficial, potentially harmful, harmful and potentially extremely harmful states.
    Bretscher PA; Ogunremi O; Menon JN
    Behring Inst Mitt; 1997 Feb; (98):153-9. PubMed ID: 9382736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective immunity against the protozoan Leishmania chagasi is induced by subclinical cutaneous infection with virulent but not avirulent organisms.
    Streit JA; Recker TJ; Filho FG; Beverley SM; Wilson ME
    J Immunol; 2001 Feb; 166(3):1921-9. PubMed ID: 11160240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-gamma-inducing oral vaccination with Leishmania amazonensis antigens protects BALB/c and C57BL/6 mice against cutaneous leishmaniasis.
    Pinto EF; de Mello Cortezia M; Rossi-Bergmann B
    Vaccine; 2003 Sep; 21(25-26):3534-41. PubMed ID: 12922080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral immunization using live Lactococcus lactis co-expressing LACK and IL-12 protects BALB/c mice against Leishmania major infection.
    Hugentobler F; Di Roberto RB; Gillard J; Cousineau B
    Vaccine; 2012 Aug; 30(39):5726-32. PubMed ID: 22814408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination using live attenuated Leishmania donovani centrin deleted parasites induces protection in dogs against Leishmania infantum.
    Fiuza JA; Gannavaram S; Santiago Hda C; Selvapandiyan A; Souza DM; Passos LS; de Mendonça LZ; Lemos-Giunchetti Dda S; Ricci ND; Bartholomeu DC; Giunchetti RC; Bueno LL; Correa-Oliveira R; Nakhasi HL; Fujiwara RT
    Vaccine; 2015 Jan; 33(2):280-8. PubMed ID: 25475955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective immune response against cutaneous leishmaniasis by prime/booster immunization regimens with vaccinia virus recombinants expressing Leishmania infantum p36/LACK and IL-12 in combination with purified p36.
    Gonzalo RM; Rodríguez JR; Rodríguez D; González-Aseguinolaza G; Larraga V; Esteban M
    Microbes Infect; 2001 Jul; 3(9):701-11. PubMed ID: 11489418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leishmania tarentolae secreting the sand fly salivary antigen PpSP15 confers protection against Leishmania major infection in a susceptible BALB/c mice model.
    Katebi A; Gholami E; Taheri T; Zahedifard F; Habibzadeh S; Taslimi Y; Shokri F; Papadopoulou B; Kamhawi S; Valenzuela JG; Rafati S
    Mol Immunol; 2015 Oct; 67(2 Pt B):501-11. PubMed ID: 26298575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repeated inoculation of killed Leishmania major induces durable immune response that protects mice against virulent challenge.
    Okwor I; Kuriakose S; Uzonna J
    Vaccine; 2010 Jul; 28(33):5451-7. PubMed ID: 20558242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis.
    Walker PS; Scharton-Kersten T; Rowton ED; Hengge U; Bouloc A; Udey MC; Vogel JC
    Hum Gene Ther; 1998 Sep; 9(13):1899-907. PubMed ID: 9741428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination against Leishmania major in a CBA mouse model of infection: role of adjuvants and mechanism of protection.
    Rivier D; Bovay P; Shah R; Didisheim S; Mauël J
    Parasite Immunol; 1999 Sep; 21(9):461-73. PubMed ID: 10476055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conditions influencing the efficacy of vaccination with live organisms against Leishmania major infection.
    Tabbara KS; Peters NC; Afrin F; Mendez S; Bertholet S; Belkaid Y; Sacks DL
    Infect Immun; 2005 Aug; 73(8):4714-22. PubMed ID: 16040984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.